The Intake Study
The study drug is being tested as a new treatment for a lung disease called idiopathic pulmonary fibrosis (IPF).
The Intake Study is exploring a new potential treatment for idiopathic pulmonary fibrosis (IPF). This condition primarily affects older adults, with a median survival of 2-5 years from diagnosis.
The study drug, administered via inhalation, aims to be more effective than current treatments available for IPF.
This study is important because it seeks to improve the treatment options for IPF, offering new hope for those affected by this serious condition.
The trial has been approved by an independent ethics committee, and eligible participants will be reimbursed for their time.
Call us at 1800 243 733 to discuss your eligibility today!